CRISPR Therapeutics Newsroom

Truist Financial Maintains CRISPR Therapeutics(CRSP.US) With Buy Rating

Futu NewsNov 20 20:33

Mizuho Securities Maintains CRISPR Therapeutics(CRSP.US) With Buy Rating

Futu NewsNov 12 16:33

Morgan Stanley Maintains CRISPR Therapeutics(CRSP.US) With Sell Rating, Maintains Target Price $45

Futu NewsNov 8 22:38

A Quick Look at Today's Ratings for CRISPR Therapeutics(CRSP.US), With a Forecast Between $30 to $95

Futu NewsNov 7 21:09

RBC Capital Reiterates Sector Perform on CRISPR Therapeutics, Maintains $53 Price Target

BenzingaNov 7 00:19

A Quick Look at Today's Ratings for CRISPR Therapeutics(CRSP.US), With a Forecast Between $30 to $94

Futu NewsNov 6 21:09

Oppenheimer Sticks to Its Buy Rating for Crispr Therapeutics AG (CRSP)

TipRanksNov 6 21:00

Analysts Offer Insights on Healthcare Companies: HCA Healthcare (HCA), Exact Sciences (EXAS) and Crispr Therapeutics AG (CRSP)

TipRanksNov 6 19:58

Crispr Therapeutics AG: Hold Rating Amid Mixed Financial Performance and Clinical Developments

TipRanksNov 6 19:55

Crispr Therapeutics Price Target Maintained With a $84.00/Share by Needham

Dow JonesNov 6 18:42

CRISPR Therapeutics Analyst Ratings

BenzingaNov 6 18:32

Barclays Remains a Hold on Crispr Therapeutics AG (CRSP)

TipRanksNov 6 16:30

Mizuho Securities Maintains CRISPR Therapeutics(CRSP.US) With Buy Rating

Futu NewsNov 5 14:32

Crispr Therapeutics AG (CRSP) Gets a Buy From Mizuho Securities

TipRanksNov 5 14:01

Truist Financial Maintains CRISPR Therapeutics(CRSP.US) With Buy Rating

Futu NewsOct 18 19:31

Truist Financial Sticks to Its Buy Rating for Crispr Therapeutics AG (CRSP)

TipRanksOct 18 19:17

CRISPR Therapeutics Analyst Ratings

BenzingaOct 4 23:35

RBC Cuts Price Target on CRISPR Therapeutics to $53 From $60, Keeps Sector Perform Rating

MT NewswiresOct 4 19:29

CRISPR Therapeutics Analyst Ratings

BenzingaAug 12 21:03

Truist Adjusts Price Target on CRISPR Therapeutics to $100 From $120, Maintains Buy Rating

MT NewswiresAug 12 18:12